Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Neuropsychiatric Symptoms in Parkinson's Disease: Beyond Complications.

Kehagia AA.

Front Psychiatry. 2016 Jun 23;7:110. doi: 10.3389/fpsyt.2016.00110. eCollection 2016. No abstract available.

2.

Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned.

Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, Behnke S, Berendse HW, Bloem BR, Burn D, Dodel R, Grosset DG, Hu M, Kasten M, Krüger R, Moccia M, Mollenhauer B, Oertel W, Suenkel U, Walter U, Wirdefeldt K, Liepelt-Scarfone I, Maetzler W, Berg D.

Front Aging Neurosci. 2016 Jun 22;8:147. doi: 10.3389/fnagi.2016.00147. eCollection 2016. Review.

3.

Associations of specific phobia and its subtypes with physical diseases: an adult community study.

Witthauer C, Ajdacic-Gross V, Meyer AH, Vollenweider P, Waeber G, Preisig M, Lieb R.

BMC Psychiatry. 2016 May 21;16:155. doi: 10.1186/s12888-016-0863-0.

4.

A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients.

Poole EM, Kubzansky LD, Sood AK, Okereke OI, Tworoger SS.

Cancer Causes Control. 2016 May;27(5):661-8. doi: 10.1007/s10552-016-0739-0. Epub 2016 Mar 29.

PMID:
27023470
5.

Depression and subsequent risk of Parkinson disease: A nationwide cohort study.

Gustafsson H, Nordström A, Nordström P.

Neurology. 2015 Jun 16;84(24):2422-9. doi: 10.1212/WNL.0000000000001684. Epub 2015 May 20.

6.

The relation between past exposure to fine particulate air pollution and prevalent anxiety: observational cohort study.

Power MC, Kioumourtzoglou MA, Hart JE, Okereke OI, Laden F, Weisskopf MG.

BMJ. 2015 Mar 24;350:h1111. doi: 10.1136/bmj.h1111.

7.

Meta-analyses on prevalence of selected Parkinson's nonmotor symptoms before and after diagnosis.

Chen H, Zhao EJ, Zhang W, Lu Y, Liu R, Huang X, Ciesielski-Jones AJ, Justice MA, Cousins DS, Peddada S.

Transl Neurodegener. 2015 Jan 8;4(1):1. doi: 10.1186/2047-9158-4-1. eCollection 2015.

8.

Psychiatric aspects of Parkinson's disease.

Grover S, Somaiya M, Kumar S, Avasthi A.

J Neurosci Rural Pract. 2015 Jan;6(1):65-76. doi: 10.4103/0976-3147.143197. Review.

9.

Walking deficits and centrophobism in an α-synuclein fly model of Parkinson's disease.

Chen AY, Wilburn P, Hao X, Tully T.

Genes Brain Behav. 2014 Nov;13(8):812-20. doi: 10.1111/gbb.12172. Epub 2014 Oct 14.

10.

Individual and joint prevalence of three nonmotor symptoms of PD in the US general population.

Chen H, Huang X, Guo X, Peddada S.

Mov Disord. 2014 Sep;29(10):1316-9. doi: 10.1002/mds.25950. Epub 2014 Jul 1.

11.

Premotor and nonmotor features of Parkinson's disease.

Goldman JG, Postuma R.

Curr Opin Neurol. 2014 Aug;27(4):434-41. doi: 10.1097/WCO.0000000000000112. Review.

12.

Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson's disease.

Sagna A, Gallo JJ, Pontone GM.

Parkinsonism Relat Disord. 2014 Jul;20(7):708-15. doi: 10.1016/j.parkreldis.2014.03.020. Epub 2014 Apr 1. Review.

13.

Anxiety in Parkinson's disease: identification and management.

Chen JJ, Marsh L.

Ther Adv Neurol Disord. 2014 Jan;7(1):52-9. doi: 10.1177/1756285613495723. Review.

14.

Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal?

Postuma RB, Gagnon JF, Tuineaig M, Bertrand JA, Latreille V, Desjardins C, Montplaisir JY.

Sleep. 2013 Nov 1;36(11):1579-85. doi: 10.5665/sleep.3102.

15.

Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.

Farrell KF, Krishnamachari S, Villanueva E, Lou H, Alerte TN, Peet E, Drolet RE, Perez RG.

J Neurochem. 2014 Feb;128(4):536-46. doi: 10.1111/jnc.12481. Epub 2013 Nov 20.

16.

Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.

Chen H, Burton EA, Ross GW, Huang X, Savica R, Abbott RD, Ascherio A, Caviness JN, Gao X, Gray KA, Hong JS, Kamel F, Jennings D, Kirshner A, Lawler C, Liu R, Miller GW, Nussbaum R, Peddada SD, Rick AC, Ritz B, Siderowf AD, Tanner CM, Tröster AI, Zhang J.

Environ Health Perspect. 2013 Nov-Dec;121(11-12):1245-52. doi: 10.1289/ehp.1306967. Epub 2013 Aug 9. Review.

17.

Relation of cumulative low-level lead exposure to depressive and phobic anxiety symptom scores in middle-age and elderly women.

Eum KD, Korrick SA, Weuve J, Okereke O, Kubzansky LD, Hu H, Weisskopf MG.

Environ Health Perspect. 2012 Jun;120(6):817-23. doi: 10.1289/ehp.1104395. Epub 2012 Feb 29.

18.

Familial aggregation of panic disturbances in Parkinson's disease.

Pontone GM, Palanci J, Bienvenu OJ, Liang KY, Nestadt G, Rabins PV, Williams JR, Marsh L.

J Neuropsychiatry Clin Neurosci. 2011 Fall;23(4):417-24. doi: 10.1176/jnp.23.4.jnp417.

19.

Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Srinivasan V, Cardinali DP, Srinivasan US, Kaur C, Brown GM, Spence DW, Hardeland R, Pandi-Perumal SR.

Ther Adv Neurol Disord. 2011 Sep;4(5):297-317. doi: 10.1177/1756285611406166.

20.

Neurobiology of depression and anxiety in Parkinson's disease.

Kano O, Ikeda K, Cridebring D, Takazawa T, Yoshii Y, Iwasaki Y.

Parkinsons Dis. 2011;2011:143547. doi: 10.4061/2011/143547. Epub 2011 May 12.

Supplemental Content

Support Center